Close Menu
  • AI
  • Content Creation
  • Tech
  • Robotics
AI-trends.todayAI-trends.today
  • AI
  • Content Creation
  • Tech
  • Robotics
Trending
  • Potential Cognition AI Spherical Would Elevate $2B-Plus at $75B Valuation – Unite.AI
  • OpenRouter Cuts Three Suppliers After AI Immediate Publicity Findings – Unite.AI
  • A Group of Researchers from Columbia and CertiK Introduce TensorLean for Formal Verification of GPU Kernels
  • Collectively AI Discloses Immediate Leak After Coding Agent Uncovered Credential – Unite.AI
  • Dragos Finds Immediate Leaks and Stolen Keys in AI Provide Chains
  • Lean and Mathlib Communities Certify Claude-Assisted Riemann Proof – Unite.AI
  • AWS Routes HyperPod Inference Throughout Areas From One Endpoint – Unite.AI
  • DailyAI Briefing: A Lean-checked Riemann proof, plus 4 extra
AI-trends.todayAI-trends.today
Home»Robotics»Mike King, Senior Director, Product & Strategy, IQVIA- Interview Series – Unite.AI

Mike King, Senior Director, Product & Strategy, IQVIA- Interview Series – Unite.AI

Robotics By Gavin Wallace22/08/20267 Mins Read
Facebook Twitter LinkedIn Email
Shahid Hanif, CEO and Co-Founder of Shufti – Interview Series
Shahid Hanif, CEO and Co-Founder of Shufti – Interview Series
Share
Facebook Twitter LinkedIn Email

Mike King, Senior Director, Product & Strategy, IQVIA (IQV )Before joining IQVIA in 2022, King held senior leadership positions at Dentsply Sirona. King served in senior management positions at Dentsply Sirona before joining IQVIA 2022. (XRAY ) As a former employee of Bio-Rad, he held quality, regulatory and operational roles. He held various roles in Bio-Rad laboratories, including quality, regulatory and operational positions. (BIO )He has worked for Accenture, Stryker and Accenture. This gives him a broad range of experience in navigating healthcare technology, compliance with regulatory requirements, and commercial strategies.

IQVIA The company is a provider of healthcare intelligence, clinical research, commercial insight, technology, domain expertise, and advanced analytics to the healthcare and life science industries. It combines advanced analytics with domain expertise and Healthcare-grade AI to support pharmaceutical, biotechnology and medical device companies in drug development, research and commercialization. IQVIA’s Connected intelligence approach aims to transform complex healthcare data and turn it into insights that will improve innovation across the entire healthcare ecosystem.

You have moved from Accenture to Stryker and Dentsply Sirona, then into regulatory and quality assurance leadership positions at GE Healthcare and IQVIA. This progression has impacted your views on long-term decisions that life sciences firms are making in the area of artificial intelligence.

In my career, I’ve worked in consulting, manufacturing and quality assurance, as well as global regulatory affairs, healthcare technology, and have been able to look at technology decisions through the eyes of multiple stakeholders. In all of my previous roles, the investments that have been most effective are those which link commercial and operational performance to patient outcomes. It is even more true when it comes to AI within the life science sector. The greatest value of AI is not efficiency, but rather the ability to enhance quality, regulatory conformity, decision making, and the provision of effective and safe healthcare in the global market.

Your argument is that AI can end the five to seven-year cycle of technology replacement. Why is it that adding AI makes a platform for quality and regulation more permanent than speeding up its replacement.

In the past, businesses replaced their systems as soon as newer technology became available or when contracts with existing providers expired. AI accelerates technological innovation, changing the calculation. Value is not confined within the app; instead, it lies in data, workflows and governance, as well institutional knowledge that has been accumulated through years of usage. Good Practices are often used to describe a set of guidelines or standards. “GxP,” In life sciences applications as organisations layer AI on validated processes, and continually improve outcomes with qualified professional oversight, an asset of intelligence is created that’s increasingly difficult to reproduce elsewhere. The decision to replace a platform, in that context, isn’t just a technological one, but also a decision about rebuilding the years-worth of organizational experience.

What is the impact of the data infrastructure and workflows in an organization on whether AI will add value to an organisation or just reinforce existing inefficiencies?

AI is amplification of the environment in which it’s deployed. AI can exacerbate inefficiencies if data fragmentation, inconsistent processes, and weak governance are present. AI can be used to increase efficiency, consistency and compliance in organizations that have standardized workflows and trusted data, as well as clear ownership and governance. Data readiness and digitalization are prerequisites to successful AI adoption. Ongoing data governance and AI Governance is essential for ensuring value, trust and compliance long after the deployment.

When an organization uses proprietary data, such as clinical and regulatory quality standards or years-old AI training to train AI systems, what is the resultant paradox?

Paradoxically, as an organization gains more success in using AI the harder it is to move away from the platform which enabled this success. Combining years of regulatory, clinical and quality data with AI can create a competitive advantage. However, it can also result in higher switching costs. Data ownership, interoperability, and portability should be built in to procurement decisions, not avoided.

You claim that technology decisions in 2025, 2026 or even 2035 could have a lasting impact on the future of 2035. Most compliance, finance and IT leaders are they adequately accounting for the extended commitment of their teams?

Companies in the life sciences industry that have been regulated are used to investing for the long term. Enterprise Resource Planning (ERP), Manufacturing, Quality, Clinical and Regulatory Systems have required planning over a multi-year horizon due to the validation of systems and change management. AI will extend these concerns, but senior leaders have already mastered the art of balancing technology risks, business objectives, and regulatory requirements. AI is different in that it emphasizes data governance and strategic value, as opposed to fundamentally altering the long-term planning process.

Life Sciences Companies: How can they be distinguished? “good lock-in,” Where accumulated intelligence and data creates a competitive edge, but also a harmful lock-in, which limits flexibility, interoperability, or negotiation power?

The best lock-in doesn’t mean you can’t leave, it just means that the platform keeps evolving. This platform protects the proprietary information and allows the adoption of new AI features and agent-native work flows as technology advances. The bad type of lock-in happens when interoperability and innovation are stifled by the provider, or years’ worth of knowledge is trapped in a system. It is important to maintain control of data and institution intelligence, while still retaining flexibility in order to benefit from the new generation of AI.

When organizations delay the replacement of aging systems, they face what kind of risks?

It is possible that outdated platforms will become bottlenecks for AI adoption. Many legacy systems contain fragmented information, manually-created workflows, and isolated processes which limit the immediate opportunities for automation. Investments in AI, predictive analytics or intelligent agents may be made by organizations only to find that the infrastructure is not scalable.

Also, there are other risks. With the aging of technologies, support from vendors may decrease, and specialist resources will be harder to locate. Maintenance costs are also likely to increase. The gap between current AI and the next generation AI platform is also widening, which makes future modernization more expensive and complex. You may find that organizations are investing in order to keep the status quo, without seeing any tangible improvement on process performance, quality of products, patient outcomes or compliance. It is often necessary to combine modernization with AI readiness rather than pursuing them as two separate projects.

How can companies protect data portability?

Organisations must focus their attention on technical and contractual protections to preserve the ownership and access of information. Included in this are clearly defined data export capabilities, open integration Frameworks, APIs that have been documented, data lineage rights, migration rights, and transparency about how proprietary models interacts with company information. This knowledge can become one of the most important assets for a business, but it needs to be portable, controlled and secure.

What are the implications of regulatory validation requirements and changes control on decisions to upgrade, retrain or replace AI-enabled medical devices and pharmaceuticals?

AI in GxP does not alter accountability. Quality and regulatory experts are responsible for the governance and integrity of systems and processes. AI-enabled technology must be supported with robust governance, risk based validation, document change control, and enough explainability in order to pass regulatory scrutiny. Human expertise from qualified professionals is an important governance element of GxP AI.

What criteria for vendor selection should companies in the life sciences industry use today to make sure that AI platforms remain secure, compliant with regulations, flexible, and economical over the next decade.

When it comes to healthcare GxP AI, companies should not just buy software but rather select a partner that can work with them. The vendor must be able to adapt their solutions with the latest technological advancements while maintaining a firm’s proprietary data and regulations. Winning platforms are those with deep life science expertise, a flexible architecture and strong governance. They also have a path that allows them to easily adopt future AI capabilities and agent native technologies, without disrupting their business, or jeopardizing global compliance.

Please visit our website for more information about this great interview. IQVIA.

AI Interview
Share. Facebook Twitter LinkedIn Email
Avatar
Gavin Wallace

Related Posts

Potential Cognition AI Spherical Would Elevate $2B-Plus at $75B Valuation – Unite.AI

22/11/2026

OpenRouter Cuts Three Suppliers After AI Immediate Publicity Findings – Unite.AI

22/11/2026

Collectively AI Discloses Immediate Leak After Coding Agent Uncovered Credential – Unite.AI

22/11/2026

Lean and Mathlib Communities Certify Claude-Assisted Riemann Proof – Unite.AI

21/11/2026
Top News

DAI#60 AI Information Roundup: Anthropic IPO, Meta’s $95B, GPT-6.1 Terra

Shivon zilis was Elon Musk’s OpenAI Insider.

California Seeks 48-Hour AI Incident Experiences and Mannequin Shutdowns

Apple Is Proper to Take a look at Its Well being Chatbot Earlier than a Full Launch

IBM and NASA create a digital twin of the sun to predict future solar storms

Load More
AI-Trends.Today

Your daily source of AI news and trends. Stay up to date with everything AI and automation!

X (Twitter) Instagram
Top Insights

1X Neo Robot with Fast Fingers

09/07/2026

The Best AI Tools for Productivity to Optimize Your Work

20/11/2025
Latest News

Potential Cognition AI Spherical Would Elevate $2B-Plus at $75B Valuation – Unite.AI

22/11/2026

OpenRouter Cuts Three Suppliers After AI Immediate Publicity Findings – Unite.AI

22/11/2026
X (Twitter) Instagram
  • Privacy Policy
  • Contact Us
  • Terms and Conditions
© 2026 AI-Trends.Today

Type above and press Enter to search. Press Esc to cancel.